Bio-Rad Maintains Its FY24 Financial Outlook
Portfolio Pulse from Benzinga Newsdesk
Bio-Rad has reaffirmed its financial outlook for FY24, expecting non-GAAP, currency-neutral revenue growth of 1.0 to 2.5 percent and a non-GAAP operating margin of 13.5 to 14.0 percent.
May 07, 2024 | 8:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bio-Rad maintains its FY24 financial outlook with expected revenue growth of 1.0 to 2.5 percent and an operating margin of 13.5 to 14.0 percent.
Reaffirming its financial outlook suggests Bio-Rad is confident in its business strategy and operational efficiency, which could positively influence investor sentiment and potentially lead to an uptick in its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100